{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:34:13Z","timestamp":1791232453618,"version":"4.1.0"},"reference-count":46,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,7,1]]},"abstract":"<jats:p>Mastocytosis is associated with an activating mutation in the KIT oncoprotein (KITD816V) that results in autophosphorylation of the KIT receptor in a ligand-independent manner. This mutation is inherently resistant to imatinib and, to date, there remains no effective curative therapy for systemic mastocytosis associated with KITD816V. Dasatinib (BMS-354825) is a novel orally bioavailable SRC\/ABL inhibitor that has activity against multiple imatinib-resistant BCR-ABL isoforms in vitro that is presently showing considerable promise in early-phase clinical trials of chronic myeloid leukemia (CML). Pharmacokinetic analysis suggests that high nanomolar concentrations of dasatinib can be achieved safely in humans. In this study, we demonstrate significant inhibitory activity of dasatinib against both wild-type KIT and the KITD816V mutation in the nanomolar range in in vitro and cell-based kinase assays. Additionally, dasatinib leads to growth inhibition of a KITD816V-harboring human masto-cytosis cell line. Significantly, dasatinib selectively kills primary neoplastic bone marrow mast cells from patients with systemic mastocytosis while sparing other hematopoietic cells. Computer modeling suggests that the KITD816V mutation destabilizes the inactive conformation of the KIT activation loop to which imatinib binds, but it is not predicted to impair binding of KIT by dasatinib. Based upon our results, further evaluation of dasatinib for the treatment of systemic masto-cytosis in clinical trials is warranted. Moreover, dasatinib may be of clinical utility in other disease settings driven by activating KIT mutations. (Blood. 2006;108:286-291)<\/jats:p>","DOI":"10.1182\/blood-2005-10-3969","type":"journal-article","created":{"date-parts":[[2006,1,24]],"date-time":"2006-01-24T22:08:53Z","timestamp":1138140533000},"page":"286-291","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":223,"title":["Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis"],"prefix":"10.1182","volume":"108","author":[{"given":"Neil P.","family":"Shah","sequence":"first","affiliation":[{"name":"From the Division of Hematology\/Oncology, The David Geffen School of Medicine at University of California-Los Angeles (UCLA), CA; Bristol-Myers Squibb Oncology, Princeton, NJ; Division of Allergy & Immunology, University of Michigan School of Medicine, Ann Arbor, MI; and University Medical Center Groningen, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis Y.","family":"Lee","sequence":"additional","affiliation":[{"name":"From the Division of Hematology\/Oncology, The David Geffen School of Medicine at University of California-Los Angeles (UCLA), CA; Bristol-Myers Squibb Oncology, Princeton, NJ; Division of Allergy & Immunology, University of Michigan School of Medicine, Ann Arbor, MI; and University Medical Center Groningen, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Luo","sequence":"additional","affiliation":[{"name":"From the Division of Hematology\/Oncology, The David Geffen School of Medicine at University of California-Los Angeles (UCLA), CA; Bristol-Myers Squibb Oncology, Princeton, NJ; Division of Allergy & Immunology, University of Michigan School of Medicine, Ann Arbor, MI; and University Medical Center Groningen, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yibin","family":"Jiang","sequence":"additional","affiliation":[{"name":"From the Division of Hematology\/Oncology, The David Geffen School of Medicine at University of California-Los Angeles (UCLA), CA; Bristol-Myers Squibb Oncology, Princeton, NJ; Division of Allergy & Immunology, University of Michigan School of Medicine, Ann Arbor, MI; and University Medical Center Groningen, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolein","family":"Donker","sequence":"additional","affiliation":[{"name":"From the Division of Hematology\/Oncology, The David Geffen School of Medicine at University of California-Los Angeles (UCLA), CA; Bristol-Myers Squibb Oncology, Princeton, NJ; Division of Allergy & Immunology, University of Michigan School of Medicine, Ann Arbor, MI; and University Medical Center Groningen, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cem","family":"Akin","sequence":"additional","affiliation":[{"name":"From the Division of Hematology\/Oncology, The David Geffen School of Medicine at University of California-Los Angeles (UCLA), CA; Bristol-Myers Squibb Oncology, Princeton, NJ; Division of Allergy & Immunology, University of Michigan School of Medicine, Ann Arbor, MI; and University Medical Center Groningen, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111823082121200_REF1","doi-asserted-by":"crossref","unstructured":"Akin C, Metcalfe DD. Systemic mastocytosis. Annu Rev Med. 2004;55: 419-432.","DOI":"10.1146\/annurev.med.55.091902.103822"},{"key":"2019111823082121200_REF2","doi-asserted-by":"crossref","unstructured":"Furitsu T, Tsujimura T, Tono T, et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest. 1993;92: 1736-1744.","DOI":"10.1172\/JCI116761"},{"key":"2019111823082121200_REF3","doi-asserted-by":"crossref","unstructured":"Nagata H, Worobec AS, Oh CK, et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have masto-cytosis with an associated hematologic disorder. Proc Natl Acad Sci U S A. 1995;92: 10560-10564.","DOI":"10.1073\/pnas.92.23.10560"},{"key":"2019111823082121200_REF4","doi-asserted-by":"crossref","unstructured":"Ma Y, Zeng S, Metcalfe DD, et al. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors;kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood. 2002;99: 1741-1744.","DOI":"10.1182\/blood.V99.5.1741"},{"key":"2019111823082121200_REF5","doi-asserted-by":"crossref","unstructured":"Akin C, Brockow K, D'Ambrosio C, et al. Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. Exp Hematol. 2003;31: 686-692.","DOI":"10.1016\/S0301-472X(03)00112-7"},{"key":"2019111823082121200_REF6","doi-asserted-by":"crossref","unstructured":"Zermati Y, De Sepulveda P, Feger F, et al. Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms. Oncogene. 2003;22: 660-664.","DOI":"10.1038\/sj.onc.1206120"},{"key":"2019111823082121200_REF7","doi-asserted-by":"crossref","unstructured":"Mol CD, Lim KB, Sridhar V, et al. Structure of a c-kit product complex reveals the basis for kinase transactivation. J Biol Chem. 2003;278: 31461-31464.","DOI":"10.1074\/jbc.C300186200"},{"key":"2019111823082121200_REF8","doi-asserted-by":"crossref","unstructured":"Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science. 2000;289: 1938-1942.","DOI":"10.1126\/science.289.5486.1938"},{"key":"2019111823082121200_REF9","doi-asserted-by":"crossref","unstructured":"Gotlib J, Berube C, Growney JD, et al. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood. 2005;106: 2865-2870.","DOI":"10.1182\/blood-2005-04-1568"},{"key":"2019111823082121200_","doi-asserted-by":"crossref","unstructured":"Tanaka A, Konno M, Muto S, et al. A novel NF-{kappa}B inhibitor, IMD-0354, suppresses neoplastic proliferation of human mast cells with constitutively activated c-kit receptors. Blood. 2005;105: 2324-2331.","DOI":"10.1182\/blood-2004-08-3247"},{"key":"2019111823082121200_","doi-asserted-by":"crossref","unstructured":"Liao AT, Chien MB, Shenoy N, et al. Inhibition of constitutively active forms of mutant kit by multi-targeted indolinone tyrosine kinase inhibitors. Blood. 2002;100: 585-593.","DOI":"10.1182\/blood-2001-12-0350"},{"key":"2019111823082121200_","doi-asserted-by":"crossref","unstructured":"Vendome J, Letard S, Martin F, et al. Molecular modeling of wild-type and D816V c-Kit inhibition based on ATP-competitive binding of ellipticine derivatives to tyrosine kinases. J Med Chem. 2005;48: 6194-6201.","DOI":"10.1021\/jm050231m"},{"key":"2019111823082121200_","doi-asserted-by":"crossref","unstructured":"Corbin AS, Griswold IJ, La Rosee P, et al. Sensitivity of oncogenic KIT mutants to the kinase inhibitors MLN518 and PD180970. Blood. 2004;104: 3754-3757.","DOI":"10.1182\/blood-2004-06-2189"},{"key":"2019111823082121200_","doi-asserted-by":"crossref","unstructured":"Corbin AS, Demehri S, Griswold IJ, et al. In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit. Blood. 2005;106: 227-234.","DOI":"10.1182\/blood-2004-12-4771"},{"key":"2019111823082121200_REF15","doi-asserted-by":"crossref","unstructured":"von Bubnoff N, Gorantla SH, Kancha RK, Lordick F, Peschel C, Duyster J. The systemic mastocytosis-specific activating cKit mutation D816V can be inhibited by the tyrosine kinase inhibitor AMN107. Leukemia. 2005;19: 1670-1671.","DOI":"10.1038\/sj.leu.2403887"},{"key":"2019111823082121200_REF16","doi-asserted-by":"crossref","unstructured":"Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004;305: 399-401.","DOI":"10.1126\/science.1099480"},{"key":"2019111823082121200_REF17","doi-asserted-by":"crossref","unstructured":"Lombardo LJ, Lee FY, Chen P, et al. Discovery of N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)-thiazole-5-carboxamide (BMS-354825), a dual Src\/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem. 2004;47: 6658-6661.","DOI":"10.1021\/jm049486a"},{"key":"2019111823082121200_REF18","doi-asserted-by":"crossref","unstructured":"O'Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 2005;65: 4500-4505.","DOI":"10.1158\/0008-5472.CAN-05-0259"},{"key":"2019111823082121200_REF19","doi-asserted-by":"crossref","unstructured":"Tkaczyk C, Metcalfe DD, Gilfillan AM. Determination of protein phosphorylation in Fc epsilon RI-activated human mast cells by immunoblot analysis requires protein extraction under denaturing conditions. J Immunol Methods. 2002;268: 239-243.","DOI":"10.1016\/S0022-1759(02)00210-7"},{"key":"2019111823082121200_REF20","doi-asserted-by":"crossref","unstructured":"Butterfield JH, Weiler D, Dewald G, Gleich GJ. Establishment of an immature mast cell line from a patient with mast cell leukemia. Leuk Res. 1988;12: 345-355.","DOI":"10.1016\/0145-2126(88)90050-1"},{"key":"2019111823082121200_REF21","doi-asserted-by":"crossref","unstructured":"Akin C, Kirshenbaum AS, Semere T, Worobec AS, Scott LM, Metcalfe DD. Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutation in T cells, B cells, and myelomonocytic cells in patients with mastocytosis. Exp Hematol. 2000;28: 140-147.","DOI":"10.1016\/S0301-472X(99)00145-9"},{"key":"2019111823082121200_REF22","doi-asserted-by":"crossref","unstructured":"Mol CD, Dougan DR, Schneider TR, et al. Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J Biol Chem. 2004;279: 31655-31663.","DOI":"10.1074\/jbc.M403319200"},{"key":"2019111823082121200_REF23","unstructured":"Nagar B, Bornmann WG, Pellicena P, et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res. 2002;62: 4236-4243."},{"key":"2019111823082121200_REF24","doi-asserted-by":"crossref","unstructured":"Akin C, Fumo G, Yavuz AS, Lipsky PE, Neckers L, Metcalfe DD. A novel form of mastocytosis associated with a transmembrane c-Kit mutation and response to imatinib. Blood. 2004;103: 3222-3225.","DOI":"10.1182\/blood-2003-11-3816"},{"key":"2019111823082121200_REF25","doi-asserted-by":"crossref","unstructured":"Valent P, Akin C, Sperr W, et al. Mastocytosis: pathology, genetics, and current options for therapy. Leuk Lymphoma. 2005;46: 35-48.","DOI":"10.1080\/10428190400010775"},{"key":"2019111823082121200_REF26","doi-asserted-by":"crossref","unstructured":"Kluin-Nelemans HC, Jansen JH, Breukelman H, et al. Response to interferon alfa-2b in a patient with systemic mastocytosis [see comments]. N Engl J Med. 1992;326: 619-623.","DOI":"10.1056\/NEJM199202273260907"},{"key":"2019111823082121200_REF27","doi-asserted-by":"crossref","unstructured":"Tefferi A, Li CY, Butterfield JH, Hoagland HC. Treatment of systemic mast-cell disease with cladribine. N Engl J Med. 2001;344: 307-309.","DOI":"10.1056\/NEJM200101253440415"},{"key":"2019111823082121200_REF28","doi-asserted-by":"crossref","unstructured":"van Oosterom AT, Judson I, Verweij J, et al. Safety and efficacy of imatinib (STI571) in meta-static gastrointestinal stromal tumours: a phase I study. Lancet. 2001;358: 1421-1423.","DOI":"10.1016\/S0140-6736(01)06535-7"},{"key":"2019111823082121200_REF29","doi-asserted-by":"crossref","unstructured":"Peng B, Hayes M, Resta D, et al. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol. 2004;22: 935-942.","DOI":"10.1200\/JCO.2004.03.050"},{"key":"2019111823082121200_REF30","doi-asserted-by":"crossref","unstructured":"Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001;293: 876-880.","DOI":"10.1126\/science.1062538"},{"key":"2019111823082121200_","doi-asserted-by":"crossref","unstructured":"Hofmann WK, de Vos S, Elashoff D, et al. Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study. Lancet. 2002;359: 481-486.","DOI":"10.1016\/S0140-6736(02)07678-X"},{"key":"2019111823082121200_","doi-asserted-by":"crossref","unstructured":"Branford S, Rudzki Z, Walsh S, et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR\/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood. 2002;99: 3472-3475.","DOI":"10.1182\/blood.V99.9.3472"},{"key":"2019111823082121200_REF33","doi-asserted-by":"crossref","unstructured":"Shah NP, Nicoll JM, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell. 2002;2: 117-125.","DOI":"10.1016\/S1535-6108(02)00096-X"},{"key":"2019111823082121200_","doi-asserted-by":"crossref","unstructured":"Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood. 2002;100: 1014-1018.","DOI":"10.1182\/blood.V100.3.1014"},{"key":"2019111823082121200_","doi-asserted-by":"crossref","unstructured":"Hochhaus A, Kreil S, Corbin AS, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia. 2002;16: 2190-2196.","DOI":"10.1038\/sj.leu.2402741"},{"key":"2019111823082121200_","doi-asserted-by":"crossref","unstructured":"von Bubnoff N, Schneller F, Peschel C, Duyster J. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet. 2002;359: 487-491.","DOI":"10.1016\/S0140-6736(02)07679-1"},{"key":"2019111823082121200_","doi-asserted-by":"crossref","unstructured":"Al-Ali HK, Heinrich MC, Lange T, et al. High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib. Hematol J. 2004;5: 55-60.","DOI":"10.1038\/sj.thj.6200319"},{"key":"2019111823082121200_","doi-asserted-by":"crossref","unstructured":"Tamborini E, Bonadiman L, Greco A, et al. A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology. 2004;127: 294-299.","DOI":"10.1053\/j.gastro.2004.02.021"},{"key":"2019111823082121200_REF39","doi-asserted-by":"crossref","unstructured":"Wardelmann E, Thomas N, Merkelbach-Bruse S, et al. Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations. Lancet Oncol. 2005;6: 249-251.","DOI":"10.1016\/S1470-2045(05)70097-8"},{"key":"2019111823082121200_REF40","doi-asserted-by":"crossref","unstructured":"Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005;352: 786-792.","DOI":"10.1056\/NEJMoa044238"},{"key":"2019111823082121200_REF41","doi-asserted-by":"crossref","unstructured":"Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005;2: e73.","DOI":"10.1371\/journal.pmed.0020073"},{"key":"2019111823082121200_REF42","doi-asserted-by":"crossref","unstructured":"Burgess MR, Skaggs BJ, Shah NP, Lee FY, Sawyers CL. Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. Proc Natl Acad Sci U S A. 2005;102: 3395-3400.","DOI":"10.1073\/pnas.0409770102"},{"key":"2019111823082121200_REF43","doi-asserted-by":"crossref","unstructured":"Carter TA, Wodicka LM, Shah NP, et al. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci U S A. 2005;102: 11011-11016.","DOI":"10.1073\/pnas.0504952102"},{"key":"2019111823082121200_REF44","doi-asserted-by":"crossref","unstructured":"Pardanani A, Ketterling RP, Brockman SR, et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood. 2003;102: 3093-3096.","DOI":"10.1182\/blood-2003-05-1627"},{"key":"2019111823082121200_REF45","doi-asserted-by":"crossref","unstructured":"Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003;348: 1201-1214.","DOI":"10.1056\/NEJMoa025217"},{"key":"2019111823082121200_REF46","doi-asserted-by":"crossref","unstructured":"Cools J, Stover EH, Boulton CL, et al. PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRalpha-induced myelo-proliferative disease. Cancer Cell. 2003;3: 459-469.","DOI":"10.1016\/S1535-6108(03)00108-9"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/108\/1\/286\/470648\/zh801306000286.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/108\/1\/286\/470648\/zh801306000286.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,12]],"date-time":"2020-04-12T04:30:16Z","timestamp":1586665816000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/108\/1\/286\/133553\/Dasatinib-BMS354825-inhibits-KITD816V-an"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7,1]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,7,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2005-10-3969","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,7,1]]}}}